{"title":"英夫利昔单抗和阿达马单抗抗tnf -a治疗对溃疡性结肠炎的疗效与常规治疗的比较:一项荟萃分析。","authors":"Zheng Zhou, Cong Dai, Wei-Xin Liu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>TNF-α has an important role in the pathogenesis of ulcerative colitis (UC). It seems that anti-TNF-α therapy is beneficial in the treatment of UC. The aim was to assess the effectiveness of Infliximab and Adalimamab with UC compared with conventional therapy.</p><p><strong>Methodology: </strong>The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab and adalimumab on UC.</p><p><strong>Results: </strong>Infliximab had a statistically significant effects in induction of clinical response (RR = 1.67; 95% CI 1.12 to 2.50) of UC compared with conventional therapy, but those had not a statistically significant effects in clinical remission (RR = 1.63; 95% CI 0.84 to 3.18) and reduction of colectomy rate (RR = 0.54; 95% CI 0.26 to 1.12) of UC. And adalimumab had a statistically significant effects in induction of clinical remission (RR = 1.82; 95% CI 1.24 to 2.67) and clinical response (RR = 1.36; 95% CI 1.13 to 1.64) of UC compared with conventional therapy.</p><p><strong>Conclusion: </strong>Our meta-analyses suggested that Infliximab had a statistically significant effects in induction of clinical response of UC compared with conventional therapy and adalimumab had a statistically significant effects in induction of clinical remission and clinical response of UC compared with conventional therapy.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 138","pages":"309-18"},"PeriodicalIF":0.0000,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.\",\"authors\":\"Zheng Zhou, Cong Dai, Wei-Xin Liu\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aims: </strong>TNF-α has an important role in the pathogenesis of ulcerative colitis (UC). It seems that anti-TNF-α therapy is beneficial in the treatment of UC. The aim was to assess the effectiveness of Infliximab and Adalimamab with UC compared with conventional therapy.</p><p><strong>Methodology: </strong>The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab and adalimumab on UC.</p><p><strong>Results: </strong>Infliximab had a statistically significant effects in induction of clinical response (RR = 1.67; 95% CI 1.12 to 2.50) of UC compared with conventional therapy, but those had not a statistically significant effects in clinical remission (RR = 1.63; 95% CI 0.84 to 3.18) and reduction of colectomy rate (RR = 0.54; 95% CI 0.26 to 1.12) of UC. And adalimumab had a statistically significant effects in induction of clinical remission (RR = 1.82; 95% CI 1.24 to 2.67) and clinical response (RR = 1.36; 95% CI 1.13 to 1.64) of UC compared with conventional therapy.</p><p><strong>Conclusion: </strong>Our meta-analyses suggested that Infliximab had a statistically significant effects in induction of clinical response of UC compared with conventional therapy and adalimumab had a statistically significant effects in induction of clinical remission and clinical response of UC compared with conventional therapy.</p>\",\"PeriodicalId\":12985,\"journal\":{\"name\":\"Hepato-gastroenterology\",\"volume\":\"62 138\",\"pages\":\"309-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepato-gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景/目的:TNF-α在溃疡性结肠炎(UC)的发病机制中起重要作用。抗肿瘤坏死因子α治疗在UC的治疗中似乎是有益的。目的是评估英夫利昔单抗和阿达木单抗与常规治疗相比治疗UC的有效性。方法:检索Pubmed和Embase数据库，研究英夫利昔单抗和阿达木单抗对UC的疗效。结果:英夫利昔单抗诱导临床反应的效果有统计学意义(RR = 1.67;95% CI 1.12 ~ 2.50)，但在临床缓解方面无统计学意义的影响(RR = 1.63;95% CI 0.84 ~ 3.18)和结肠切除术率降低(RR = 0.54;95% CI 0.26 ~ 1.12)。阿达木单抗在诱导临床缓解方面具有统计学意义(RR = 1.82;95% CI 1.24 ~ 2.67)和临床反应(RR = 1.36;与常规治疗相比，UC的95% CI为1.13至1.64。结论:我们的荟萃分析表明，与常规治疗相比，英夫利昔单抗在诱导UC临床反应方面具有统计学意义，阿达木单抗在诱导UC临床缓解和临床反应方面具有统计学意义。
Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Background/aims: TNF-α has an important role in the pathogenesis of ulcerative colitis (UC). It seems that anti-TNF-α therapy is beneficial in the treatment of UC. The aim was to assess the effectiveness of Infliximab and Adalimamab with UC compared with conventional therapy.
Methodology: The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab and adalimumab on UC.
Results: Infliximab had a statistically significant effects in induction of clinical response (RR = 1.67; 95% CI 1.12 to 2.50) of UC compared with conventional therapy, but those had not a statistically significant effects in clinical remission (RR = 1.63; 95% CI 0.84 to 3.18) and reduction of colectomy rate (RR = 0.54; 95% CI 0.26 to 1.12) of UC. And adalimumab had a statistically significant effects in induction of clinical remission (RR = 1.82; 95% CI 1.24 to 2.67) and clinical response (RR = 1.36; 95% CI 1.13 to 1.64) of UC compared with conventional therapy.
Conclusion: Our meta-analyses suggested that Infliximab had a statistically significant effects in induction of clinical response of UC compared with conventional therapy and adalimumab had a statistically significant effects in induction of clinical remission and clinical response of UC compared with conventional therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
